# A fasting-mimicking environment enhances procaspase-activating compound 1 in 2D and 3D glioma cell models

## TL;DR

A fasting-like environment improves the effectiveness of a cancer drug in brain cancer cell models.

## Contribution

This study is the first to show that fasting-mimicking conditions enhance PAC-1's effect in 2D and 3D glioma models.

## Key findings

- Fasting-mimicking conditions reduced PAC-1's IC50 and increased apoptosis in glioma cell monolayers.
- Minimum PAC-1 concentration needed to reduce spheroid area was lower under fasting-mimicking conditions.
- Serum restriction was identified as the main factor behind the enhanced drug effect.

## Abstract

Glioblastoma multiforme (GBM) is the most common form of malignant brain cancer and is generally approached with palliative intent. Preclinical studies suggest that short-term fasting may be an effective tool for enhancing existing cancer therapies by disrupting the glucose-dependent, oncogenic phenotype of many cancers. In this study, we investigated whether a fasting-mimicking environment (FME) enhances the efficacy of an emerging proapoptotic drug, procaspase-activating compound 1 (PAC-1), in 2D and 3D GBM cell models. Ad libitum food consumption (Fed) and FME conditions were simulated in vitro by modifying glucose, ketone and serum concentrations. The FME conditions enhanced PAC-1 in U87-MG, T98G and 9L-GS monolayer experiments by significantly reducing the PAC-1 50% inhibitory concentration (IC50), delaying cell growth and increasing apoptosis. Similarly, in the 3D spheroid models, the minimum concentration of PAC-1 required to reduce U87-MG and 9L-GS spheroid area was lower in the FME conditions than the Fed conditions. Additionally, we discovered that serum restriction was primarily responsible for the FME-induced PAC-1 enhancement. These finding are the first to demonstrate that fasting-mimicking conditions sensitize 2D and 3D glioma cell models to PAC-1, supporting the use of short-term fasting as a low-cost and widely accessible strategy for enhancing cancer therapies.